Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Prestige Consumer Healthcare Inc. or Ligand Pharmaceuticals Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated compare based on key financial metrics to determine which better meets your investment needs.

About Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Latest Pharmaceuticals and Prestige Consumer Healthcare Inc., Ligand Pharmaceuticals Incorporated Stock News

As of August 14, 2026, Prestige Consumer Healthcare Inc. had a $2.4 billion market capitalization, compared to the Pharmaceuticals median of $587.7 million. Prestige Consumer Healthcare Inc.’s stock is down 16.7% in 2026, down 6.3% in the previous five trading days and down 22.66% in the past year.

Currently, Prestige Consumer Healthcare Inc.’s price-earnings ratio is 14.4. Prestige Consumer Healthcare Inc.’s trailing 12-month revenue is $1.1 billion with a 15.6% net profit margin. Year-over-year quarterly sales growth most recently was 6.5%. Analysts expect adjusted earnings to reach $4.590 per share for the current fiscal year. Prestige Consumer Healthcare Inc. does not currently pay a dividend.

As of August 14, 2026, Ligand Pharmaceuticals Incorporated had a $5.9 billion market cap, putting it in the 69th percentile of all stocks. Ligand Pharmaceuticals Incorporated’s stock is up 55.8% in 2026, up 0.5% in the previous five trading days and up 88.84% in the past year.

Currently, Ligand Pharmaceuticals Incorporated’s price-earnings ratio is 32.0. Ligand Pharmaceuticals Incorporated’s trailing 12-month revenue is $290.5 million with a 67.9% net profit margin. Year-over-year quarterly sales growth most recently was 33.8%. Analysts expect adjusted earnings to reach $9.315 per share for the current fiscal year. Ligand Pharmaceuticals Incorporated does not currently pay a dividend.

How We Compare Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated Stock Value Grades

Company	Ticker	Value
Prestige Consumer Healthcare Inc.	PBH	A
Ligand Pharmaceuticals Incorporated	LGND	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Prestige Consumer Healthcare Inc. has a Value Score of 81, which is Deep Value. Ligand Pharmaceuticals Incorporated has a Value Score of 10, which is Ultra Expensive.

The Value Stock Winner: Prestige Consumer Healthcare Inc.

As you can clearly see from the Value Grade breakdown above, Prestige Consumer Healthcare Inc. is considered to have better value than Ligand Pharmaceuticals Incorporated. For investors who focus solely on a company’s valuation, Prestige Consumer Healthcare Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated’s Momentum Grades

Company	Ticker	Momentum
Prestige Consumer Healthcare Inc.	PBH	D
Ligand Pharmaceuticals Incorporated	LGND	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Prestige Consumer Healthcare Inc. has a Momentum Score of 32, which is Weak. Ligand Pharmaceuticals Incorporated has a Momentum Score of 89, which is Very Strong.

The Momentum Grade Winner: Ligand Pharmaceuticals Incorporated

As you can clearly see from the Momentum Grade breakdown above, Ligand Pharmaceuticals Incorporated is considered to have stronger momentum compared to Prestige Consumer Healthcare Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Ligand Pharmaceuticals Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Prestige Consumer Healthcare Inc.	PBH	C
Ligand Pharmaceuticals Incorporated	LGND	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Prestige Consumer Healthcare Inc. has a Earnings Estimate Score of 45, which is Neutral. Ligand Pharmaceuticals Incorporated has a Earnings Estimate Score of 46, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Prestige Consumer Healthcare Inc. or Ligand Pharmaceuticals Incorporated has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Prestige Consumer Healthcare Inc. or Ligand Pharmaceuticals Incorporated is the better investment when it comes to estimate revisions.

Other Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Prestige Consumer Healthcare Inc. or Ligand Pharmaceuticals Incorporated Stock?

Overall, Prestige Consumer Healthcare Inc. stock has a Value Score of 81, Momentum Score of 32 and Estimate Revisions Score of 45.

Ligand Pharmaceuticals Incorporated stock has a Value Score of 10, Momentum Score of 89 and Estimate Revisions Score of 46.

Comparing Prestige Consumer Healthcare Inc. and Ligand Pharmaceuticals Incorporated’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.